VERONA PHARMA ($VRNA) posted quarterly earnings results on Wednesday, August 6th. The company reported earnings of $0.13 per share, beating estimates of -$0.02 by $0.15. The company also reported revenue of $103,140,000, beating estimates of $94,042,470 by $9,097,530.
You can see Quiver Quantitative's $VRNA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
VERONA PHARMA Insider Trading Activity
VERONA PHARMA insiders have traded $VRNA stock on the open market 41 times in the past 6 months. Of those trades, 0 have been purchases and 41 have been sales.
Here’s a breakdown of recent trading of $VRNA stock by insiders over the last 6 months:
- DAVID ZACCARDELLI (President and CEO) has made 0 purchases and 9 sales selling 1,686,280 shares for an estimated $17,163,687.
- MARK W HAHN (Chief Financial Officer) has made 0 purchases and 9 sales selling 1,686,280 shares for an estimated $17,163,092.
- KATHLEEN A. RICKARD (Chief Medical Officer) has made 0 purchases and 6 sales selling 336,168 shares for an estimated $3,192,153.
- ANDREW FISHER (General Counsel) has made 0 purchases and 4 sales selling 195,656 shares for an estimated $1,967,695.
- VIKAS SINHA has made 0 purchases and 4 sales selling 184,328 shares for an estimated $1,738,229.
- CHRISTINA ACKERMANN has made 0 purchases and 2 sales selling 41,808 shares for an estimated $361,363.
- MICHAEL AUSTWICK sold 11,288 shares for an estimated $148,366
- MARTIN EDWARDS sold 10,808 shares for an estimated $142,057
- KENNETH CUNNINGHAM sold 10,808 shares for an estimated $142,057
- LISA DESCHAMPS sold 9,464 shares for an estimated $124,391
- MAHENDRA SHAH sold 3,608 shares for an estimated $47,422
- DAVID R EBSWORTH sold 1,904 shares for an estimated $25,025
- JAMES ALOYSIUS BRADY sold 824 shares for an estimated $10,830
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
VERONA PHARMA Hedge Fund Activity
We have seen 145 institutional investors add shares of VERONA PHARMA stock to their portfolio, and 121 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANUS HENDERSON GROUP PLC added 3,849,724 shares (+230.9%) to their portfolio in Q1 2025, for an estimated $244,418,976
- DARWIN GLOBAL MANAGEMENT, LTD. added 3,112,755 shares (+384.1%) to their portfolio in Q1 2025, for an estimated $197,628,814
- NEA MANAGEMENT COMPANY, LLC removed 2,896,188 shares (-51.9%) from their portfolio in Q1 2025, for an estimated $183,878,976
- RA CAPITAL MANAGEMENT, L.P. removed 1,766,830 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $112,176,036
- HOLOCENE ADVISORS, LP added 1,366,680 shares (+inf%) to their portfolio in Q1 2025, for an estimated $86,770,513
- MAVERICK CAPITAL LTD removed 1,345,018 shares (-43.0%) from their portfolio in Q1 2025, for an estimated $85,395,192
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 1,292,575 shares (+381.9%) to their portfolio in Q1 2025, for an estimated $82,065,586
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
VERONA PHARMA Analyst Ratings
Wall Street analysts have issued reports on $VRNA in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wolfe Research issued a "Outperform" rating on 07/01/2025
- Piper Sandler issued a "Overweight" rating on 06/23/2025
- Wells Fargo issued a "Overweight" rating on 06/20/2025
- Roth Capital issued a "Buy" rating on 06/18/2025
- Cantor Fitzgerald issued a "Overweight" rating on 06/11/2025
To track analyst ratings and price targets for VERONA PHARMA, check out Quiver Quantitative's $VRNA forecast page.
VERONA PHARMA Price Targets
Multiple analysts have issued price targets for $VRNA recently. We have seen 10 analysts offer price targets for $VRNA in the last 6 months, with a median target of $107.0.
Here are some recent targets:
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $107.0 on 07/14/2025
- Tiago Fauth from Wells Fargo set a target price of $107.0 on 07/10/2025
- Suji Jeong from Jefferies set a target price of $107.0 on 07/09/2025
- Edward Nash from Canaccord Genuity set a target price of $107.0 on 07/09/2025
- Andy Chen from Wolfe Research set a target price of $170.0 on 07/01/2025
- Yasmeen Rahimi from Piper Sandler set a target price of $160.0 on 06/23/2025
- Boobalan Pachaiyappan from Roth Capital set a target price of $116.0 on 06/18/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
